A61K 2039/82
Colon
Official title: {Colon}
A61K2039/82 (Colon) appears on 60 US grants and 175 published applications in this corpus.
Search patents in A61K- Granted patents
- 60
- Published applications
- 175
- Assignees
- 112
- Inventors
- 437
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 2 |
| 2003 | 0 | 1 |
| 2004 | 0 | 4 |
| 2005 | 0 | 2 |
| 2006 | 0 | 2 |
| 2007 | 0 | 0 |
| 2008 | 1 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 1 | 2 |
| 2018 | 0 | 2 |
| 2019 | 1 | 15 |
| 2020 | 5 | 15 |
| 2021 | 5 | 23 |
| 2022 | 7 | 33 |
| 2023 | 12 | 18 |
| 2024 | 9 | 29 |
| 2025 | 14 | 14 |
| 2026 | 5 | 11 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Intracellular delivery of biomolecules to modify immune response8 Sep 2026US 12,728,163 B2Stemcell Technologies Canada Inc.
- Compositions and methods for cancer therapy25 Aug 2026US 12,714,723 B2AIM ImmunoTech Inc.
- Oncolytic virus therapy2 Jun 2026US 12,642,832 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Polymeric nanovaccines and uses thereof3 Mar 2026US 12,564,643 B2Ramot at Tel-Aviv University Ltd.
- Vaccines for treating SARS infections in cancer patients6 Jan 2026US 12,516,296 B2City of Hope
- Tumor Immunotherapy10 Sep 2026US 2026/0263573 A1Peking University Shenzhen Graduate School
- Tumor cell vaccines20 Aug 2026US 2026/0240969 A1Neuvogen, Inc.
- Methods and compositions for combination therapy13 Aug 2026US 2026/0232766 A1Msd International Business GmbH
- Vaccines against clostridioides difficile and methods of using the same13 Aug 2026US 2026/0232785 A1
- Compositions comprising neoantigens and methods of enhancing anti-pd1 therapy25 Jun 2026US 2026/0174837 A1Geneos Therapetucis, Inc.
Most cited
By later US patents
- Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers7US 10,400,011 B2Immatics Biotechnologies GmbH · 2019
- Compositions and methods for the induction of CD8+ T-cells6US 10,695,412 B2Keio University · 2020
- Compositions and methods for the induction of CD8+ T-cells6US 11,167,018 B2Keio University · 2021
- Compositions and method for optimized peptide vaccines using residue optimization6US 11,464,842 B1Think Therapeutics, Inc. · 2022
- Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer5US 11,338,027 B2Amal Therapeutics SA · 2022